Dear Mr. Gremban:

Please refer to your supplemental new drug applications dated October 30, 2001, received October 31, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zyvox™ (linezolid tablets) Tablets (NDA 21-130/S-002); Zyvox™ (linezolid injection) I.V. Injection (NDA 21-131/S-002); and Zyvox™ (linezolid for oral suspension) for Oral Suspension (NDA 21-132/S-002).

We acknowledge receipt of your submissions dated March 22, and December 18, 2002.

These supplemental new drug applications provide for the addition of the following language to the Postmarketing Experience subsection of the label:

"Neuropathy (peripheral, optic) has been reported in patients treated with ZYVOX. Although these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days, these events have also been reported in patients receiving shorter courses of therapy."

We completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) submitted December 18, 2002.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 21-130/S-002, NDA 21-131/S-002, and NDA 21-132/S-002." Approval of these submissions by FDA is not required before the labeling is used.
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD  20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Beth Duvall-Miller, Regulatory Health Project Manager, at (301) 827-2125.

Sincerely yours,

{See appended electronic signature page}

Janice M. Soreth, M.D.
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Janice Soreth
12/19/02 11:54:49 AM